ERAS Projected Dividend Yield
Erasca Inc ( NASDAQ : ERAS )Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Co.'s primary product candidates are ERAS-007 (its oral ERK1/2 inhibitor) and ERAS-601 (its oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. The extracellular signal-regulated kinases (ERK), ERK1 and ERK2, belong to a family of serine-threonine kinases that regulate cellular signaling, and comprise the terminal node of the RAS/MAPK pathway-driven cancers. Co. is pursuing a clinical development plan across multiple tumor types for ERAS-007. 20 YEAR PERFORMANCE RESULTS |
ERAS Dividend History Detail ERAS Dividend News ERAS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |